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Hurler syndrome (HS), the most severe phenotype in the spec-
trum of MPS I, is caused by a severe deficiency of the lysosomal en-
zyme alpha-L-iduronidase (IDUA). At present, hematopoietic stem
cell transplantation (HSCT) is the only treatment able to prevent
disease progression in the central nervous system and therefore con-
sidered the treatment of choice in HS patients. Since IDUA enzyme
levels after HSCT have been suggested to influence the prognosis of
HS patients, monitoring these levels after HSCT remains highly im-
portant. The current standard for biochemical monitoring after
HSCT is the leukocyte IDUA enzyme level. There is however
a high inter-laboratory variability concerning the analysis of leuko-
cyte IDUA, which makes enzyme level comparison between centers
very difficult. The use of dried blood spot (DBS) for enzyme analysis
has already been demonstrated to be an easier and less expensive
method. Furthermore, this method requires only a minimal amount
of blood and makes worldwide shipment feasible. DBS analysis
would therefore be more suitable for use in large-scale international
studies.
From 13HS patients receivingHSCT, 35 paired whole blood and
DBS samples were analyzed on leukocyte and DBS IDUA levels, re-
spectively. In order to correct for potential interfering factors, simul-
taneous assay of the alpha-Galactosidase-A (AGA) level was
performed in the DBS samples and an IDUA-AGA-ratio was calcu-
lated. A strong correlation was demonstrated between the DBS
IDUA-AGA-ratio and the leukocyte IDUA levels (r25 0,875,
p\0,001). This linear correlation was applicable to all enzyme
levels, including the levels measured early after HSCT as well as het-
erozygous levels due to mixed chimerism or the use of a carrier do-
nor. These results demonstrate that the DBS method is reliable to
monitor the biochemical effect of HSCT in HS patients. This
method is therefore a useful alternative to the conventional leukocyte
assay during the follow-up of HS patients after HSCT as well as dur-
ing large-scale international studies. In the future, the DBS method
might be extended towards monitoring the biochemical effect of
HSCT or any future therapy (eg gene therapy) on other lysosomal
storage disorders.237
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Bronchiolitis obliterans (BO) is one of the most challenging
late noninfectious complications of allogeneic hematopoietic
stem cell transplantation (HSCT). BO is associated with a pro-
gressive decline of pulmonary function secondary to air flow ob-
struction and overall survival of only 13% at 5 years. Treatment
strategies mirror that of chronic GVHD consisting of systemiccorticosteroids and augmentation or re-institution of immuno-
suppressive therapy. Response is poor with a 3-year mortality
rate of 65% when BO accompanies cGVHD. Total lymphoid ir-
radiation (TLI) has been used with some success for the treat-
ment of BO following lung transplantation but has not been
reported in the treatment of BO following allo-HSCT. We pres-
ent two pediatric patients who received TLI for refractory BO
after unrelated peripheral blood stem cell transplant (PBSCT).
The diagnosis of BO was made by an irreversible obstructive pat-
tern on pulmonary function testing, CT scans with bilateral air
trapping, and absence of infection. BO progressed despite aggres-
sive therapy with corticosteroids, tacrolimus, mycophenolate mo-
fetil, and etanercept. Patient 1 is a 15 year-old who underwent
a 9/10 (one C allele mismatch) PBSCT in 2005 for secondary
AML with TLI initiated at 30 months after PBSCT. Patient 2
is a 9 year-old who had a 10/10 PBSCT in 2006 for relapsed
ALL with TLI initiated at 26 months after PBSCT. Patients re-
ceived a total of 80 cGy of irradiation delivered in two 8 cGy
fractions per week for a total of 10 fractions. Treatment was
well tolerated with grade 1 thrombocytopenia in patient 1 and
grade 2 anemia and grade 3 thrombocytopenia in patient 2 per
CTCAE v 3.0. Patient 1 had no further decline in FEV1 with
improvement in FEV1/FVC and FEF 25%-75% at 6 months af-
ter TLI but died at 11 months post TLI due to multiple infec-
tions. Patient 2 had a dramatic increase in FEV1, FEV1/FVC,
and FEF 25%-75% that remains sustained at 10 months post
TLI. These results strongly suggest that TLI is a useful modality
in the treatment of refractory BO following allo-HSCT and
should be evaluated in future studies.
Table 1. Pulmonary Function Tests Before and After Total
Lymphoid Irradiation (TLI)
Patient #1 TLI Patient #2
at 30 months TLI at 26 monthsTime after PBSCT
FEV1 %
predictedFEV1/
FVCFEF 25% -
75% %
predicted
FEV1 %
predictedFEV1/
FVCFEF 25% -
75% %
predicted12 months 75% 92% 93% 96% 100% 118%
18 months 71% 89% 92% 93% 96% 119%
23 months 62% 80% 55% 70% 94% 102%
26 months 46% 73% 27% 54% 88% 48%
30 months 47% 67% 27% 78% 93% 101%
36 months 48% 77% 37% 95% 99% 124%Abbreviations: PBSCT (peripheral blood stem cell transplant)238
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Compared to older adults, the role of NM-HCT to cure pediatric
malignancies is not well-established and has typically been reserved
for high-risk patients (pts).We conducted a retrospective multi-cen-
ter analysis of all pts who were\22 yrs old with hematological ma-
lignancies treated on protocol to determine factors associated with
outcome after NM-HCT. Between Jan 2001-July 2008, 26 pts
with a median age of 17.9 (5.1-21.9) yrs were treated for ALL
(CR1,n5 1;CR2,n5 3;CR3,n5 5), AML (CR2,n5 5; CR4,n5 1;
PR, n5 1), Hodgkin lymphoma (CR1,n5 1; CR3, n5 2;
PR,n5 2;Ref,n5 1), MDS (n5 2), or NHL (CR3, n5 1; Rel,
n5 1). NM-HCT was chosen for concern of increased regimen-
related toxicity due to comorbidities alone (n5 11) or prior
